Resverlogix Corp
Company Profile
Business description
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Contact
4820 Richard Road South West
Suite 300
CalgaryABT3E 6L1
CANT: +1 403 254-9252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
18
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,579.90 | 50.10 | 0.59% |
| CAC 40 | 7,886.69 | 33.22 | 0.42% |
| DAX 40 | 23,767.43 | 71.84 | 0.30% |
| Dow JONES (US) | 42,654.74 | 331.99 | 0.78% |
| FTSE 100 | 8,684.56 | 50.81 | 0.59% |
| HKSE | 23,345.05 | 108.11 | -0.46% |
| NASDAQ | 19,211.10 | 98.78 | 0.52% |
| Nikkei 225 | 37,753.72 | 1.79 | -0.00% |
| NZX 50 Index | 12,786.79 | 94.03 | -0.73% |
| S&P 500 | 5,958.38 | 41.45 | 0.70% |
| S&P/ASX 200 | 8,343.70 | 46.20 | 0.56% |
| SSE Composite Index | 3,367.46 | 13.36 | -0.40% |